Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

盘前交易 05-22 04:51:25 EDT

7.52

+0.32

+4.44%

盘前7.66

+0.14+1.86%

04:43 EDT

最高7.79	最低7.03	成交量63.17万
今开7.10	昨收7.20	日振幅10.56%
总市值2.35亿	流通市值1.18亿	总股本3,129万
成交额475.52万	换手率4.03%	流通股本1,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":7.52,"timestamp":1779393600000,"preClose":7.2,"halted":0,"volume":631732,"hourTrading":{"tag":"盘前","latestPrice":7.66,"preClose":7.52,"latestTime":"04:43 EDT","volume":215,"amount":1604.46545,"timestamp":1779439402550,"change":0.14,"changeRate":0.018617,"amplitude":0.040253},"delay":0,"changeRate":0.04444444444444436,"floatShares":15692500,"shares":31289969,"eps":-3.661292,"marketStatus":"盘前交易","change":0.32,"latestTime":"05-22 04:51:25 EDT","open":7.1,"high":7.79,"low":7.03,"amount":4755223.64896,"amplitude":0.105556,"askPrice":8.43,"askSize":100,"bidPrice":6.85,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779456600000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":7.52,"preHourTrading":{"tag":"盘前","latestPrice":7.66,"preClose":7.52,"latestTime":"04:43 EDT","volume":215,"amount":1604.46545,"timestamp":1779439402550,"change":0.14,"changeRate":0.018617,"amplitude":0.040253},"postHourTrading":{"tag":"盘后","latestPrice":7.38,"preClose":7.52,"latestTime":"19:47 EDT","volume":3288,"amount":24613.1,"timestamp":1779407263101,"change":-0.14,"changeRate":-0.018617,"amplitude":0.018617},"volumeRatio":0.6682335134368481,"impliedVol":0.7318,"impliedVolPercentile":0.144},"requestUrl":"/m/hq/s/LENZ/","defaultTab":"news","newsList":[{"id":"2635035245","title":"Indaptus Therapeutics Q1净亏损收窄，现金储备大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035245","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035245?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:46","pubTimestamp":1778859960,"startTime":"0","endTime":"0","summary":"　　Indaptus Therapeutics公布2026年第一季度财报。公司报告期内净亏损为254万美元，合每股亏损0.23美元，较上年同期的453万美元亏损和每股亏损9.11美元显著收窄。每股亏损的大幅减少主要源于2025年6月实施的1比28反向股票分割带来的股份数量增加。一般及行政费用为167万美元，同比略有下降。　　截至季末，公司现金及现金等价物仅为150万美元，较2025年末的850万美元大幅下降。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6357238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4588","BK4505","RNA","BK4139","BK4585","BK4539","BMS","BK4007","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635359547","title":"Aptevo Therapeutics公布一季度业绩及临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2635359547","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635359547?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:49","pubTimestamp":1778683740,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Aptevo Therapeutics周三发布2026年第一季度业务更新，披露现金储备及核心管线试验的最新进展。公司同步宣布完成管理层交接。　　截至2026年3月31日，Aptevo持有现金及现金等价物1450万美元。　　公司同步宣布完成管理层过渡，新任命的首席执行官表示，核心药物持续产生令人信服的一线数据，将强效缓解活性与差异化的安全性特征相结合，有潜力成为标准疗法的重要补充。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxunaz7338741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109919604","title":"Piper Sandler下调Lenz Therapeutics评级至中性，目标价大幅削减至12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109919604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109919604?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:34","pubTimestamp":1778553253,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler宣布，将生物技术公司Lenz Therapeutics的股票评级从“增持”下调至“中性”。与此同时，该机构大幅调降了对该公司的目标股价，从此前的39美元大幅削减至12美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634465519","title":"美股异动 | Odyssey Therapeutics(ODTX.US)登陆美股市场 开盘股价波动不大","url":"https://stock-news.laohu8.com/highlight/detail?id=2634465519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634465519?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:00","pubTimestamp":1778256000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Odyssey Therapeutics(ODTX.US)登陆美股市场，开盘股价波动不大，IPO价格为18美元。截至发稿，该股跌超1%，报17.81美元。Odyssey Therapeutics是一家总部位于美国波士顿的临床阶段生物科技公司，主要专注于自身免疫性及炎症性疾病药物研发。公司核心产品为OD-001，这是一款用于治疗溃疡性结肠炎的小分子药物，目前已进入中期临床试验阶段。此外，公司还布局红斑狼疮、特应性皮炎等多个免疫疾病管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ODTX","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450362","title":"Atossa Therapeutics一季度GAAP每股亏损1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450362","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633450362?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:49","pubTimestamp":1778251740,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Atossa Therapeutics公布2026年第一季度财报，GAAP每股亏损1.11美元。由于公司尚无商业化产品，本季度未录得营收。　　财报显示，公司一季度净亏损约1.38亿美元，较上年同期净亏损650万美元大幅扩大。剔除一次性项目后，调整后每股亏损约为0.18美元。截至3月31日，公司持有现金及短期投资约1.15亿美元，较年初减少约2000万美元。　　财报发布后，Atossa股价在盘后交易中下跌约5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfamz4272189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UUP","UDN","BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633902722","title":"拜耳斥资24.5亿美元收购Perfuse Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2633902722","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633902722?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:02","pubTimestamp":1778054520,"startTime":"0","endTime":"0","summary":"德国拜耳公司周三宣布，将收购生物制药公司Perfuse Therapeutics，以完善其眼科产品线。\n　　拜耳在一份声明中表示，该交易潜在价值高达24.5亿美元，其中包括3亿美元的首付款，以及根据研发、监管和商业里程碑进展情况支付的额外款项。\n　　该交易将使拜耳获得PER-001的全部权益。PER-001是一种小分子内皮素受体拮抗剂（ERA），目前正处于II期临床开发阶段，用于治疗青光眼和糖尿病视网膜病变。\n　　拜耳表示，此次收购将在获得必要的反垄断审批和Perfuse股东批准后生效。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：于健 SF069","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-06/doc-inhwxxki3422808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632511159","title":"亿腾嘉和(06998)：Candid Therapeutics被UCB收购 首付款20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632511159","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632511159?lang=zh_cn&edition=full","pubTime":"2026-05-04 22:51","pubTimestamp":1777906296,"startTime":"0","endTime":"0","summary":"于2024年9月，Candid Therapeutics, Inc.与TRC 2004, Inc.合并。集团与Candid Therapeutics订立了日期为2025年3月28日的修订协议，以修订及补充许可协议的若干条款，共同推动GB261在自身免疫领域的临床开发。于2026年5月3日，于布鲁塞尔泛欧交易所上市的比利时医药集团Union Chimique Belge宣布已签署一项最终协议，据此其将收购 Candid Therapeutics。根据协议条款，UCB须支付首付款20亿美元，连同高达2亿美元的潜在未来里程碑付款，惟须视乎是否达成指定里程碑而定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","06998","BK1574","BK4139","LENZ","BK4539","UCB","BK4007","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107930113","title":"LENZ Therapeutics将于2026年5月11日公布第一季度财报并参与投资者会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107930113","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107930113?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896178,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年5月4日——专注商业化VIZZ1.44%的制药企业LENZ Therapeutics宣布，将于2026年5月11日东部时间下午4:30举行网络直播，披露2026年第一季度财务业绩及近期公司动态。该产品是全球首个且唯一获FDA批准的醋克利定滴眼液，用于治疗成人老花眼。直播链接亦可在LENZ Therapeutics官网的\"投资者与媒体\"专区获取。此外，公司管理层将于2026年5月13日至14日出席在拉斯维加斯举行的美国银行全球医疗健康大会，并安排一对一会议。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4539","BK4139","R","BK4022","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136316695","title":"Avalo Therapeutics达成里程碑付款买断协议 优化资本结构","url":"https://stock-news.laohu8.com/highlight/detail?id=1136316695","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136316695?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:15","pubTimestamp":1777374917,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Avalo Therapeutics Inc  近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852486","title":"美国FDA拒绝批准Grace Therapeutics脑卒中药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852486","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852486?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:43","pubTimestamp":1776969780,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日已向Grace Therapeutics发出完整回应函，拒绝批准其候选药物治疗特定类型脑卒中（中风）的上市申请。FDA在函件中指出，根据现有数据，暂无法确认该药物的临床获益大于风险，并要求公司在药品获批前补充相关的临床试验数据或生产质量控制信息。　　Grace Therapeutics方面随即回应称，正对FDA的反馈进行详细评估。　　此次拒绝为该公司的新药上市之路增加了新的不确定性，至于Grace是选择提起上诉还是重新提交申请，还有待公司进一步披露。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5066320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","BK4007","BK4139","LENZ","BK4539","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115266921","title":"Trevi Therapeutics完成1.73亿美元承销发行 承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1115266921","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115266921?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715692,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics近日宣布，其此前公布的承销公开发行已正式完成。本次发行以每股13.00美元的价格公开发行13,340,000股普通股，其中包括承销商全额行使期权，以发行价额外购买的1,740,000股普通股。在扣除承销折扣和佣金前，本次发行总收益约为1.73亿美元。所有发行股份均由Trevi公司售出。Trevi拟将Haduvio作为口服纳布啡缓释片的商品名。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","BK4516","LU0795875169.SGD","LU1074936037.SGD","LU2089283258.USD","LU1548497426.USD","BK4127","LU0267386448.USD","LU1162221912.USD","LU0882574139.USD","BK4588","LU2271345857.HKD","LU1720051017.SGD","LENZ","BK4139","BK4555","LU2111349929.HKD","LU1791710582.SGD","TRVI","IE00BKVL7J92.USD","LU1244550577.SGD","BK4007","LU0912757837.SGD","LU1732800096.USD","LU2028103732.USD","RCC","BK4534","LU0106261372.USD","BK4539","IE00BZ1G4Q59.USD","BK4604","LU0106831901.USD","BK4585","LU0234570918.USD","LU0557290698.USD","LU1363072403.SGD","LU0158827948.USD","LU1244550494.USD","LU2089284900.SGD","LU0528227936.USD","LU0225283273.USD","BK4099","LU1989772923.USD","BK4581","LU0320765646.SGD","03160","LU0098860793.USD","LU1244550221.USD","LU0158827781.USD","LU1732799900.SGD","LU2357305700.SGD","LU2347655156.SGD","MS","TM","LU0971096721.USD","LU0314104364.USD","LU2023251221.USD","LU0006306889.USD","LU2133065610.SGD","LU1791710400.SGD","LU1989772840.SGD","LU0795875086.SGD","BK4504","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126480925","title":"Lenz Therapeutics向英国药监局提交Vizz®老花眼治疗药物上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1126480925","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126480925?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:00","pubTimestamp":1776686431,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司已正式向英国药品和保健品监管局提交了Vizz®药物的上市许可申请，该药物主要用于治疗老花眼。此次申请标志着该疗法在英国市场商业化进程的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628578522?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场，开盘暴涨超50%，报24.1美元，IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年，是一家处于临床后期的生物科技公司，正在开发四种基于GLP-1的减肥药物，其中包括一款每周注射一次的药物和一款每日口服一次的药片，目前均已进入后期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4539","KLRA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138495751","title":"Trevi Therapeutics宣布拟进行普通股公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1138495751","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138495751?lang=zh_cn&edition=full","pubTime":"2026-04-17 04:11","pubTimestamp":1776370286,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics今日宣布，已启动承销式公开发行，计划发售总值1.5亿美元的普通股。本次发行全部股份均由Trevi提供。公司还拟授予承销商30天超额配售选择权，可额外认购最多2250万美元的普通股，发行价格将扣除承销折扣与佣金。摩根士丹利、Leerink Partners、Cantor及Stifel担任此次发行的联席账簿管理人，Oppenheimer & Co.则出任牵头经理。Trevi计划将Haduvio作为口服纳布啡缓释片的商品名，其安全性与有效性尚未获得任何监管机构评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","LU0528227936.USD","LU0106831901.USD","LU1244550221.USD","IE00BKVL7J92.USD","LU2023251221.USD","LU2133065610.SGD","BK4127","LU0106261372.USD","TRVI","BK4555","LU1548497426.USD","LU1791710400.SGD","LU0795875086.SGD","BK4534","MS","LU0320765646.SGD","LU1720051017.SGD","LU1791710582.SGD","LU0006306889.USD","LU2271345857.HKD","BK4099","BK4604","BK4516","LU2089283258.USD","LU1244550577.SGD","LU0971096721.USD","LU1732800096.USD","LU2028103732.USD","LU2089284900.SGD","LU2347655156.SGD","TM","LU1074936037.SGD","BK4581","LENZ","LU0158827781.USD","LU0098860793.USD","LU0267386448.USD","LU1720051108.HKD","LU0234570918.USD","LU1989772923.USD","LU1732799900.SGD","BK4588","LU0314104364.USD","LU0557290698.USD","LU2111349929.HKD","BK4539","IE00BZ1G4Q59.USD","RCC","LU0158827948.USD","BK4139","LU0912757837.SGD","03160","BK4007","BK4585","LU1363072403.SGD","LU1162221912.USD","LU0225283273.USD","LU0795875169.SGD","LU2357305700.SGD","LU1244550494.USD","LU0882574139.USD","LU1668664300.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195745157","title":"Xilio Therapeutics任命Cheryl R. Blanchard博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1195745157","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195745157?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:33","pubTimestamp":1776339227,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年4月16日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，任命Cheryl R. Blanchard博士加入公司董事会。公司同时公告，Christina Rossi已于2026年4月15日卸任董事职务。Cheryl R. Blanchard博士为Xilio带来逾30年领导经验，在生命科学企业具备深厚的科研、运营与商业管理背景。Xilio Therapeutics是一家临床阶段生物技术公司，致力于研发掩蔽型免疫肿瘤疗法，旨在显著提升癌症患者疗效的同时避免现有治疗引发的全身性副作用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115849765","title":"Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1115849765","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115849765?lang=zh_cn&edition=full","pubTime":"2026-04-15 04:07","pubTimestamp":1776197275,"startTime":"0","endTime":"0","summary":"旧金山，2026年4月14日——临床阶段全球生物制药公司Structure Therapeutics Inc.今日宣布，任命Matthew Lang, J.D. 为公司首席运营官兼总法律顾问。Lang先生在加入Structure Therapeutics时，已在全球生物制药机构拥有超过十五年的高管领导经验，其深厚专长涵盖法律、企业战略、合规、风险管理和业务发展等多个领域。Structure Therapeutics首席执行官Raymond Stevens博士表示：\"Matt是一位经验丰富的领导者，在引导组织实现增长和转型方面拥有卓越的业绩记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4232","R","BK4599","BK4022","BK4007","GPCR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627482480","title":"凝血障碍生物技术公司Hemab Therapeutics(COAG.US)申请在美上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627482480","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627482480?lang=zh_cn&edition=full","pubTime":"2026-04-13 14:36","pubTimestamp":1776062174,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics上周五向SEC提交申请，计划通过首次公开募股(IPO)筹集至多1亿美元资金。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260413/20260413143653_79739.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260413/20260413143653_79739.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","IPOS","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626213871","title":"C4 Therapeutics与罗氏扩大合作，达成逾10亿美元新癌症药物协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626213871","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626213871?lang=zh_cn&edition=full","pubTime":"2026-04-09 22:01","pubTimestamp":1775743260,"startTime":"0","endTime":"0","summary":"C4 Therapeutics周四宣布，已与瑞士制药巨头罗氏签署一项新的合作协议，共同研发新型癌症药物，交易总价值有望超过10亿美元。　　此次合作将聚焦于一种新兴的癌症疗法——降解剂-抗体偶联物。　　C4 Therapeutics：利用其专有的TORPEDO平台设计具有payload特性的降解剂候选分子。　　C4 Therapeutics将获得2000万美元的预付款。罗氏业务发展全球负责人Boris Zatra表示：“我们与C4 Therapeutics的关系建立在十年的信任和共同的科学追求之上”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-09/doc-inhtxkar8629046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LENZ","BK4539","CCCC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139966539","title":"Outlook Therapeutics完成500万美元公开发行募资","url":"https://stock-news.laohu8.com/highlight/detail?id=1139966539","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139966539?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:07","pubTimestamp":1774469224,"startTime":"0","endTime":"0","summary":"新泽西州艾斯林2026年3月25日电——专注于提升视网膜疾病治疗标准生物制药企业Outlook Therapeutics, Inc.今日宣布，已完成此前公布的2000万股普通股及配套认股权证公开发行。每份认股权证可额外认购1股普通股，发行单元定价为0.25美元。认股权证行权价每股0.25美元，即日生效，有效期五年。本次发行扣除承销费用前的总收益为500万美元。若认股权证全部以现金行权，公司有望再获约500万美元资金注入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","LENZ","BK4539","03160","BK4099","BK4588","BK4585","BK4139","BK4604","BK4555","TM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.0316},{"period":"1month","weight":-0.2381},{"period":"3month","weight":-0.3512},{"period":"6month","weight":-0.7456},{"period":"1year","weight":-0.7329},{"period":"ytd","weight":-0.53}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.14005},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}